Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.60 |
| ▸ | NAE1 | Q13564 | 3/20 | 0.53 |
| ▸ | UBA3 | Q8TBC4 | 3/20 | 0.53 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795319 | 0.84 | CA2 (0.55) | NAE1UBA3CA2 | |
| SCHEMBL23080273 | 0.84 | CA2 (0.55) | NAE1UBA3CA2 | |
| SCHEMBL17875220 | 0.83 | SLC29A1 (0.60) | ADORA3NAE1UBA3DNPH1TP53 | |
| SCHEMBL10186161 | 0.83 | SLC29A1 (0.60) | ADORA3NAE1UBA3DNPH1TP53 | |
| SCHEMBL1796246 | 0.83 | SLC29A1 (0.60) | ADORA3NAE1UBA3DNPH1TP53 | |
| SCHEMBL12566881 | 0.83 | CA2 (0.53) | NAE1UBA3DNPH1CA2 | |
| SCHEMBL17889870 | 0.82 | DNPH1 (0.75) | ADORA3NAE1UBA3DNPH1TP53 | |
| SCHEMBL1796735 | 0.82 | DNPH1 (0.75) | ADORA3NAE1UBA3DNPH1TP53 | |
| SCHEMBL1795912 | 0.81 | ADORA3 (0.63) | ADORA3DNPH1TP53SLC29A1TDP1 | |
| SCHEMBL1949613 | 0.80 | DNPH1 (0.65) | ADORA3NAE1UBA3DNPH1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ADORA3 1669/4885NAE1 257/4885UBA3 235/4885 |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ADORA3 1669/4885NAE1 257/4885UBA3 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.